Oral drugs to halt neurodegeneration Origami Therapeutics, Inc. is a biotech company developing novel protein degraders with potential to delay or halt disease progression by eliminating toxic proteins from the body. Our drug discovery platform leverages our...
Targeted protein degradation (TPD) is emerging to be a promising technology for targeting disease-causing proteins. Through the mechanism of hijacking either the ubiquitin-proteasome system (UPS) or the autophagy-lysosomal pathway the protein of interest is degraded,...
The Huntington’s Disease Society of America (HDSA) is proud to announce that Jeff Carroll, PhD and Beth Hoffman, PhD have been elected to the Society’s National Board of Trustees. Learn...
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
